3631 results for «372»
3631 results
Mitral TEER intraprocedural guidance
11 Sep 2025 – From PCR Rio Valves 2025
This session offers a detailed exploration of mitral TEER intraprocedural guidance through case-based learning. It highlights step-by-step techniques, including post-processing and key questions interventionalists face regarding residual regurgitation, clip insertion, and evaluating final procedural outcomes.
EuroPCR 2025 Closing Ceremony
23 May 2025 – From EuroPCR 2025
Conclude your conference experience with the EuroPCR 2025 Closing Ceremony, celebrating the achievements, innovations, and advancements presented throughout the event, and setting the stage for future developments in interventional cardiology.
Jon DeHaan Foundation Award & Michele Pighi Young Investigator Award
21 May 2025 – From EuroPCR 2025
Celebrate innovation and research excellence in interventional cardiology with the Jon DeHaan Foundation Award and Michele Pighi Young Investigator Award session. This session highlights groundbreaking work and emerging talent shaping the future of cardiovascular interventions.
Coronary sinus reducer for microvascular angina
28 Feb 2020
A 61-year-old man with a history of 2-vessel coronary artery stenting, hypertension and type-2 diabetes mellitus was admitted 5 times within September 2017 and November 2018 for recurrent angina CCS class III-IV refractory to therapy with nitrates, b-blockers and ranolazine in maximally tolerated doses...
EuroPCR 2019 Press Release: A pragmatic approach to defining high bleeding risk for patients undergoing in PCI
22 May 2019
Paris, France, 22 May 2019. Identification and management of patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI) is of major importance, but a lack of standardisation in defining this population limits trial design, data interpretation, and clinical decision-making.
Concomitant left atrial appendage occlusion and transcatheter aortic valve replacement among patients with atrial fibrillation – The WATCH-TAVR Trial
26 Oct 2023
Panos Xaplanteris provides his take on WATCH-TAVR results which were presented by Samir R. Kapadia at TCT Congress 2023.
Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve Replacement - The WATCH TAVR Trial

Author
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.

Author
EuroPCR 2019 Press Release: Education rhymed with interaction at the world-leading course in interventional cardiovascular medicine
24 May 2019
Paris, France, 24 May 2019. A total of 11,206 participants from over 120 different countries were present at the 30th edition of EuroPCR. An additional 4,700 online learners connected to watch a selection of sessions that were made available both live and on replay via PCR...
The FLAVOUR Randomized Clinical Trial: Comparison of Fractional Flow Reserve-guided and Intravascular Ultrasound-guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Stenosis
22 Mar 2022
Daniele Giacoppo analyses the main results of the FLAVOUR trial which were presented by Bon-Kwon Koo, from Seoul National University Hospital, South Korea at the American College of Cardiology 2022.

Author
SCOPE I: A randomized trial of the ACURATE Neo vs. the SAPIEN 3 bioprosthesis in patients with severe aortic stenosis - TCT 2019
28 Sep 2019
The results of the SCOPE I trial were presented at TCT 2019 in San Francisco by Jonas Lanz, Bern University Hospital. Read the analysis by Fabien Praz.

Author
Five-year outcomes of the randomised trial of fractional flow reserve guided PCI compared to coronary artery bypass grafting: FAME 3
02 Apr 2025
Kalaivani Mahadevan provides her take on the five-year outcomes of the FAME 3 trial presented by William F. Fearon at ACC.25 in Chicago.

Author